For the Inventor, By the Inventor

Enter assignee name

Telangana, India

Hetero Labs Limited

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 20.0

EPO Patents = 5

Forward Citations = 15

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Parthasaradhi Reddy Bandi (8 out of 8 patents)

Kura Rathnakar Reddy (7 out of 94 patents)

Bandi Parthasaradhi Reddy (6 out of 96 patents)

4. Panduranga Reddy Adulla (5 out of 5 patents)

5. Rathnakar Reddy Kura (5 out of 5 patents)

6. Bandi Vamsi Krishna (4 out of 42 patents)

7. Khadgapathi Podile (3 out of 3 patents)

8. Sunil Deviprasad Tiwari (3 out of 3 patents)

9. David Krupadanam Gazula Levi (3 out of 3 patents)

10. Theodore John Nitz (3 out of 45 patents)

11. Carl Thomas Wild (3 out of 19 patents)

12. David Eugene Martin (3 out of 4 patents)

13. Bhaskar Reddy Kasireddy (3 out of 3 patents)

14. Prakash Shetiya (2 out of 2 patents)

15. Adulla Panduranga Reddy (2 out of 2 patents)

15 patents: Sort by Forward Citations

1. 12378281 - Triterpenone derivatives as HIV inhibitors (2025-08-05),

2. 12275712 - Triterpene derivatives as HIV inhibitors (2025-04-14),

3. 11655220 - Process for the preparation of angiotensin II receptor blockers (2023-05-23),

4. 11471447 - Stable pharmaceutical product and vessel comprising sodium picosulfate, magnesium oxide and citric acid (2022-10-18),

5. 11045423 - Anti-retroviral compositions (2021-06-29),

6. 11034718 - C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors (2021-06-15),

7. 11020351 - Stable bilayer tablet compositions (2021-06-01),

8. 10822314 - Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound (2020-11-03),

9. 10669305 - C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors (2020-06-02),

10. 10562867 - Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound (2020-02-18),

11. 10533035 - C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors (2020-01-14),

12. 10370405 - C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors (2019-08-06),

13. 10329281 - Polymorphs and process for the preparation of quinazolinyl derivatives (2019-06-25),

14. 10214497 - Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound (2019-02-26),

15. 9868758 - Betulinic proline imidazole derivatives as HIV inhibitors (2018-01-16),

Company Overview

Hetero Labs Limited is a prominent pharmaceutical company based in Telangana, India, specializing in the development and manufacturing of a diverse range of generic and specialty medications. The company focuses on areas such as oncology, anti-retrovirals, and other therapeutic segments, leveraging advanced technologies to enhance drug efficacy and accessibility. Hetero Labs is committed to innovation in drug formulation and delivery, aiming to improve patient outcomes through high-quality pharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#2 in Telangana

#126 in India

#39,991 in the World

Telangana, India

Hetero Labs Limited

Forward Citations = 15

32 inventors:

Parthasaradhi Reddy Bandi (8 out of 8 patents)

Kura Rathnakar Reddy (7 out of 94 patents)

Bandi Parthasaradhi Reddy (6 out of 96 patents)

4. Panduranga Reddy Adulla (5 out of 5 patents)

5. Rathnakar Reddy Kura (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hetero Labs Limited. Retrieved from https://idiyas.com/company/hetero-labs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…